Infrastructure wins in diagnostics, AI embeds in workflows, and serial testing drives oncology revenue

By DripPublished

The gist

This week, diagnostics is moving from standalone tests and tools to embedded infrastructure, recurring workflows, and monetizable platforms that capture more of the care pathway.

This week’s developments

Decentralized Testing Is Becoming an Infrastructure Category

RDi USA’s launch of an automated, end-to-end self-sampling platform is the clearest sign that decentralized diagnostics is shifting from point products to infrastructure. The system combines high-throughput, camera-verified kit manufacturing reportedly at hundreds of thousands of kits per day with sample-return logistics, lab integration, and the +CURA digital workflow, tying ordering, activation, self-collection, return, and results delivery into one operating layer.

The platform spans blood, urine, and more than 150 registered kits and is aimed at population screening, decentralized clinical trials, occupational health, and pharmacy or retail diagnostics rather than single-brand consumer testing. FDA actions are widening the market beyond infectious disease: the FDA-cleared Freenome SimpleScreen CRC blood test for average-risk colorectal cancer screening in adults 45+ and the FDA-authorized at-home HPV self-testing kit both move remote specimen collection into cancer and women’s health. Abbott’s commercialization of Freenome, including exclusive U.S. rights and a stated roughly $100 million milestone, shows regulated distributed testing is becoming a viable go-to-market model, not just a clinical proof point.

What infrastructure capabilities will capture value as decentralized testing scales?

If you operate in this industry

  • Decentralized testing is becoming the operating layer, not a feature.
  • Build or partner for end-to-end workflow control now, or risk being reduced to a commodity assay in a platform-owned channel.

Sources

If you sell into this industry

  • Buyers want integrated kit-to-result infrastructure, not standalone tools.
  • Shift roadmap and GTM toward workflow, logistics, and compliance integration; point products will lose budget to platform bundles.

Sources

If you invest in this industry

  • Platform owners are capturing the value in decentralized diagnostics.
  • Favor infrastructure and regulated workflow platforms; point-test and single-use kit bets face margin and distribution pressure.

Sources

Diagnostic AI Is Shifting Into EHR-Native Workflow Infrastructure

Lapsi Health moved its Keikku Clinical AI platform from standalone use into the EHR workflow, a meaningful step because it turns diagnostic AI into chart-ready infrastructure rather than a separate tool. Keikku now generates clinician-facing SOAP notes, ICD-10/CPT coding, and auscultation artifacts, then pushes them into the patient chart through PDF, HL7/FHIR, or API integrations. Its Redox partnership materially broadens reach: Redox connects to more than 12,000 healthcare organizations and 100-plus EHRs, and Keikku already supports Epic, Oracle Cerner, eClinicalWorks, and Elation.

The platform combines ambient conversation audio for documentation with FDA-cleared digital stethoscope data for murmur and lung sound analysis. That combination matters strategically: diagnostics value is shifting toward systems that are billable, interoperable, and usable at the point of care, not just accurate in isolation. Lapsi’s move ties interpretation directly to documentation and reimbursement-adjacent workflows, raising the premium on enterprise compliance and integration depth. Function Health’s $450 million raise points in the same direction from the consumer side, with capital still favoring platforms that bundle diagnostics, longitudinal data, and navigation over isolated features.

How should we adapt product and go-to-market for EHR-native AI?

If you operate in this industry

  • AI wins when it lands in the chart, not when it sits beside it.
  • Prioritize EHR-native workflows, coding, and auditability; standalone diagnostic AI is getting commoditized fast.

Sources

If you sell into this industry

  • Integration depth is now the product, not a sales add-on.
  • Shift roadmap and GTM toward EHR-native APIs, HL7/FHIR, and compliance; budget follows workflow-embedded tools.

Sources

If you invest in this industry

  • Value is moving to interoperable platforms that touch reimbursement.
  • Favor companies bundling diagnostics, documentation, and navigation; point tools without EHR reach face multiple pressure.

Sources

Oxford BioDynamics and Foundation Medicine Show the Next Monetization Layer

Oxford BioDynamics’ first paid EpiSwitch Orion deal is small in disclosed economics but strategically important: the OPTIMISE collaboration converts a newly launched platform into third-party revenue and pushes Orion into psoriatic arthritis biomarker discovery, beyond the company’s more visible prostate cancer and immuno-oncology work. The deal also shows the platform is being sold as an execution stack, not just an assay, spanning wet-lab work, bioinformatics, machine-learning model development, validation, and a final predictive classifier.

The same week, Cofactor Genomics added a chief medical officer to support its RNA rollout, underscoring that commercialization infrastructure is being built around platform deployment rather than a single-test launch. Foundation Medicine added five companion diagnostic approvals in the first half of 2026 across FoundationOne CDx and FoundationOne Liquid CDx, while FDA De Novo authorization for CaRi-Heart on July 29, 2026, extended imaging AI into routine CCTA decision support. After last week’s emphasis on validation and reimbursement, the next step is monetization at scale: platforms that can prove repeatable revenue, regulatory reach, and clinical utility across indications, modalities, and care settings will be the ones practitioners can actually build around.

Where will platform revenue and margin accrue next?

If you operate in this industry

  • Revenue now comes from platforms, not just single assays.
  • Build for repeatable multi-indication monetization or risk being outpaced by platforms selling wet lab, analytics, and validation as one stack.

Sources

If you sell into this industry

  • Buyers want commercialization infrastructure, not just a test.
  • Shift roadmap and GTM toward deployment support, regulatory breadth, and model validation—budget is moving to full-stack execution.

Sources

If you invest in this industry

  • Platform monetization is proving out beyond pilot-stage hype.
  • Favor companies with regulatory reach and repeatable revenue across indications; point tools without expansion paths look increasingly fragile.

Sources

Serial Blood Testing Is Becoming the Economic Engine in Oncology

Adaptive’s latest utilization data shows why blood-based oncology is moving from one-off assays to recurring care workflows: 73% of orders since launch were serial, blood-based MRD accounted for 49% of MRD tests, and adoption has spread to more than 6,100 oncologists and 1,800 centers. That matters because the value proposition is shifting from test performance alone to repeat use, longitudinal data, and workflow lock-in.

At the same time, large prospective and validation studies are making screening assays more clinically legible and easier to operationalize, which should widen the addressable market for serial testing. Beckman Coulter’s recent moves in liquid biopsy sample prep and AI-ready lab automation reinforce the enabling layer behind that shift, even without a Cleo-linked announcement. For operators and investors, the competitive edge is moving toward platforms that can capture repeat ordering, manage data over time, and plug into automated lab infrastructure rather than standalone assays sold as single events.

Where will recurring oncology workflow value accrue next?

If you operate in this industry

  • Serial testing is becoming the moat, not the assay itself.
  • Build for repeat ordering, longitudinal data, and workflow stickiness—or risk being reduced to a commoditized test in someone else’s platform.

Sources

If you sell into this industry

  • Demand is shifting to platforms that support recurring oncology workflows.
  • Prioritize serial-use features, data continuity, and automation integration; one-off assay performance alone won’t win enterprise budgets.

If you invest in this industry

  • Recurring oncology workflows are where value is concentrating.
  • Favor platforms with repeat utilization and lab integration; standalone assays face margin and multiple pressure as serial testing scales.

Sources

Stay ahead in Diagnostics & Informatics

Get the weekly Diagnostics & Informatics brief in your inbox — the developments, what they mean by vantage, and what to do next.